SV2002000761A - Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv - Google Patents

Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv

Info

Publication number
SV2002000761A
SV2002000761A SV2001000761A SV2001000761A SV2002000761A SV 2002000761 A SV2002000761 A SV 2002000761A SV 2001000761 A SV2001000761 A SV 2001000761A SV 2001000761 A SV2001000761 A SV 2001000761A SV 2002000761 A SV2002000761 A SV 2002000761A
Authority
SV
El Salvador
Prior art keywords
pirrolo
dihydroisoquinolins
ref
read
dihydroisoquinolines
Prior art date
Application number
SV2001000761A
Other languages
English (en)
Spanish (es)
Inventor
Ulrich Niewohner
Marcus Bauser
Jens-Kerim Erguden
Dietmar Flubacher
Paul Naab
Thorsten-Oliver Repp
Juergen Stoltefuss
Buks Burkhardt
Andrea Sewing
Michael Schauer
Karl-Heinz Schlemmer
Olaf Weber
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV2002000761A publication Critical patent/SV2002000761A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SV2001000761A 2000-12-13 2001-12-12 Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv SV2002000761A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25520600P 2000-12-13 2000-12-13
US31031201P 2001-08-06 2001-08-06

Publications (1)

Publication Number Publication Date
SV2002000761A true SV2002000761A (es) 2002-12-02

Family

ID=26944520

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000761A SV2002000761A (es) 2000-12-13 2001-12-12 Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv

Country Status (10)

Country Link
US (1) US6930114B2 (enExample)
EP (1) EP1347973A1 (enExample)
JP (1) JP2004517843A (enExample)
AU (1) AU2002227985A1 (enExample)
CA (1) CA2431326A1 (enExample)
HN (1) HN2001000277A (enExample)
PE (1) PE20021085A1 (enExample)
SV (1) SV2002000761A (enExample)
UY (1) UY27067A1 (enExample)
WO (1) WO2002048144A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014116A1 (en) * 2001-08-06 2003-02-20 Bayer Corporation Pyrrolo[2.1-a]isoquinoline derivatives
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
WO2003051877A1 (en) * 2001-12-18 2003-06-26 Bayer Corporation 2-substituted pyrrolo[2.1-a]isoquinolines against cancer
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US7135480B2 (en) * 2002-12-12 2006-11-14 Cytovia, Inc. Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis
KR20060030483A (ko) * 2003-06-30 2006-04-10 알타나 파마 아게 Ｐｄｅ10 억제제로서 피롤로디히드로이소퀴놀린
CA2530114A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
ATE430148T1 (de) * 2005-01-12 2009-05-15 Nycomed Gmbh Neue pyrrolodihydroisochinoline als pde10- inhibitoren
EP1838708A2 (en) * 2005-01-12 2007-10-03 Nycomed GmbH Pyrrolodihydroisoquinolines as antiproliferative agents
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008001182A1 (en) * 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200944523A (en) * 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9127015B2 (en) 2009-12-04 2015-09-08 Nerviano Medical Sciences S.R.L. Tricyclopyrazole derivatives
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE690792A (enExample) * 1966-12-07 1967-05-16
FR7348M (enExample) * 1967-12-07 1969-10-13
US4719216A (en) * 1983-06-23 1988-01-12 Mcneilab, Inc. Hexahydropyrrolo(2,1-A)isoquinoline derivatives as antidepressants
DE3401018A1 (de) * 1984-01-13 1985-07-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung von 5,6-dihydro-pyrrolo(2,1-a)isochinolinen
GB8718980D0 (en) * 1987-08-11 1987-09-16 May & Baker Ltd Compositions of matter
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
US6673564B2 (en) 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
US20040138249A1 (en) 2004-07-15
AU2002227985A1 (en) 2002-06-24
JP2004517843A (ja) 2004-06-17
UY27067A1 (es) 2002-07-31
CA2431326A1 (en) 2002-06-20
WO2002048144A1 (en) 2002-06-20
EP1347973A1 (en) 2003-10-01
HN2001000277A (es) 2002-01-30
PE20021085A1 (es) 2003-05-16
US6930114B2 (en) 2005-08-16

Similar Documents

Publication Publication Date Title
UY27067A1 (es) Pirrolo (2.-a) dihidroisoquinolinas
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
HN2001000146A (es) Derivados de pirazol
UY26285A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
IL152115A0 (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors
ATE253576T1 (de) 8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren
TR200001041T2 (tr) Opioid analjezik ve sayklooksijenaz-2 inhibitörünün sinerjistik analjezik kombinasyonu.
HUP0302615A3 (en) Kinase inhibitor quinazoline derivatives and pharmaceutical compositions containing them and their use
CY1119536T1 (el) Συνθεση μονομερων προστατευμενου 3'-αμινο νουκλεοζιδιου
CR9465A (es) Compuestos mejorados farmacocineticamente
DK1193270T3 (da) Pyrrolobenzodiazepiner
HN2003000227A (es) Inhibidores de quinasas
DK1150982T3 (da) Purininhibitorer af cylkineafhængig kinase 2 og 1kB-alfa
MXPA03006420A (es) Diaminotiazoles.
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
BR9912327A (pt) Inibidores da uroquinase
NO20024806D0 (no) Apomorfinderivater samt anvendelse derav
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
UY27610A1 (es) Combinación de inhibidores de ptm o inhibidores de la secreción de apob con fibratos para la utilización como medicamentos
CY1108773T1 (el) 7-υδροξυεπιανδροστερονη που εχει νευροπροστατευτικη δραση
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ES2121817T3 (es) Inhibidor de la agregacion plaquetaria inducida por el colageno.
GT199800081A (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para el tratamiento delcancer.
HN2002000278A (es) Tetrahidroquinolinas